DK2406263T3 - Pyrazolo[1,5-a]-1,3,5-triazinderivater, deres fremstilling samt deres terapeutiske anvendelse - Google Patents

Pyrazolo[1,5-a]-1,3,5-triazinderivater, deres fremstilling samt deres terapeutiske anvendelse

Info

Publication number
DK2406263T3
DK2406263T3 DK10710681.7T DK10710681T DK2406263T3 DK 2406263 T3 DK2406263 T3 DK 2406263T3 DK 10710681 T DK10710681 T DK 10710681T DK 2406263 T3 DK2406263 T3 DK 2406263T3
Authority
DK
Denmark
Prior art keywords
pyrazolo
preparation
therapeutic use
triazine derivatives
triazine
Prior art date
Application number
DK10710681.7T
Other languages
English (en)
Inventor
Laurent Meijer
Herve Galons
Benoit Joseph
Florence Popowycz
Nassima Oumata
Original Assignee
Centre Nat Rech Scient
Univ Paris Descartes
Univ Claude Bernard Lyon
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Univ Paris Descartes, Univ Claude Bernard Lyon, Inst Nat Sante Rech Med filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of DK2406263T3 publication Critical patent/DK2406263T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
DK10710681.7T 2009-03-11 2010-03-11 Pyrazolo[1,5-a]-1,3,5-triazinderivater, deres fremstilling samt deres terapeutiske anvendelse DK2406263T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15924609P 2009-03-11 2009-03-11
FR0951521A FR2943058B1 (fr) 2009-03-11 2009-03-11 Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique.
PCT/IB2010/051063 WO2010103486A1 (fr) 2009-03-11 2010-03-11 Derives de pyrazolo[1,5-a]-1,3,5-triazines, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
DK2406263T3 true DK2406263T3 (da) 2014-01-13

Family

ID=41110928

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10710681.7T DK2406263T3 (da) 2009-03-11 2010-03-11 Pyrazolo[1,5-a]-1,3,5-triazinderivater, deres fremstilling samt deres terapeutiske anvendelse

Country Status (8)

Country Link
US (1) US8691982B2 (da)
EP (1) EP2406263B1 (da)
JP (1) JP2012520288A (da)
CA (1) CA2753135A1 (da)
DK (1) DK2406263T3 (da)
ES (1) ES2440323T3 (da)
FR (1) FR2943058B1 (da)
WO (1) WO2010103486A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120083498A1 (en) * 2010-06-17 2012-04-05 Fatah Kashanchi Modulators of Viral Transcription, and Methods and Compositions Therewith
US20120149708A1 (en) * 2010-06-17 2012-06-14 George Mason University Modulators of viral transcription, and methods and compositions therewith
EP2602248A1 (en) 2011-12-05 2013-06-12 University Of Leicester Novel pyrrole compounds
EP2634190A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
EP2634189A1 (en) * 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
WO2014189830A1 (en) 2013-05-20 2014-11-27 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Calcium channel agonists
CN107530329B (zh) * 2015-03-09 2021-10-08 奥瑞基尼探索技术有限公司 用作CDK抑制剂的吡唑并[1,5-a][1,3,5]三嗪和吡唑并[1,5-a]嘧啶衍生物
US10722513B2 (en) * 2015-03-23 2020-07-28 The University Of Melbourne Treatment of respiratory diseases
WO2016193939A1 (en) 2015-06-04 2016-12-08 Aurigene Discovery Technologies Limited Substituted heterocyclyl derivatives as cdk inhibitors
WO2016206999A1 (en) 2015-06-24 2016-12-29 Apodemus Ab Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
RU2770363C2 (ru) 2017-04-05 2022-04-15 Куровир Аб Гетероароматические соединения, пригодные в терапии
EP3877382B1 (en) 2018-11-07 2026-03-18 Tianli Biotech Pty Ltd Novel compounds for the treatment of respiratory diseases
CN111217814B (zh) * 2018-11-26 2022-08-26 天津科技大学 一类联哌啶衍生物及其作为抗肿瘤药物的应用
CN112479956A (zh) * 2019-07-30 2021-03-12 杭州阿诺生物医药科技有限公司 一种用于制备腺苷受体抑制剂中间体的方法
EP4512806A1 (en) * 2023-08-25 2025-02-26 Mablink Bioscience Molecular glue degraders and uses thereof
EP4512427A1 (en) * 2023-08-25 2025-02-26 Mablink Bioscience Antibody-drug conjugates based on molecular glue degraders and uses thereof
CN119707984A (zh) * 2023-09-28 2025-03-28 中国科学院上海药物研究所 吡唑并三嗪及吡唑并嘧啶衍生物、其制备方法、药物组合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627633B2 (en) * 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
CA2432417A1 (fr) 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
US6812232B2 (en) 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
FR2842809A1 (fr) 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
TW200536536A (en) * 2004-02-25 2005-11-16 Schering Corp Pyrazolotriazines as kinase inhibitors

Also Published As

Publication number Publication date
US20120184557A1 (en) 2012-07-19
WO2010103486A1 (fr) 2010-09-16
EP2406263A1 (fr) 2012-01-18
FR2943058A1 (fr) 2010-09-17
US8691982B2 (en) 2014-04-08
EP2406263B1 (fr) 2013-09-25
FR2943058B1 (fr) 2011-06-03
CA2753135A1 (fr) 2010-09-16
JP2012520288A (ja) 2012-09-06
ES2440323T3 (es) 2014-01-28

Similar Documents

Publication Publication Date Title
IL249651A0 (en) Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[b-2,1] 4,2,1]]triazin-2-yl]benzamide and processes related to their preparation
IL223253B (en) 2-(piperidin-2-yl)-pyrazolo[1,5-a]pyrimidine derivatives and their use for preparing anti-pneumovirinae medicaments
ZA201000075B (en) Purin derivatives for use in the treatment of fab-related diseases
IL210802A0 (en) Purin derivatives for use in the treatment of fab-related diseases
PT3001903T (pt) 1h-pirazolo[3,4-b]piridinas e usos terapêuticos destas
FR2943058B1 (fr) Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique.
PL2935274T3 (pl) Pochodne 3-okso-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pirymidyny do leczenia chorób układu oddechowego
IL209840A0 (en) Azacarboline derivatives, preparation thereof, and therapeutic use thereof as kinase inhibitors
DK2146991T3 (da) Triazolopyridin-carboxamid-derivater, fremstilling af samme samt terapeutisk anvendelse deraf
BR112013022948A2 (pt) derivados de pirido [2,3 - b] pirazina e seus usos terapêuticos
PT2448940E (pt) Derivados de 6,7,8,9-tetra-hidro-pirimido{1,2-α} pirimidin- 4-ona, sua preparação e sua utilização farmacêutica
PT3030563T (pt) Derivados de pirrolo[3,2-d]pirimidina para o tratamento de infeções virais e outras doenças
IL233808B (en) History of triazole[5,4-d]pyrimidine and drugs containing them
PL2448939T3 (pl) Pochodne 2,3-dihydro-1h-imidazo {1,2-a} pirymidyn-5-onu, ich wytwarzanie i ich zastosowanie farmaceutyczne
IL215286A0 (en) 9h-pyrrolo[2,3-b:5,4-c]dipridine azacarboline derivatives, preparation thereof, and therapeutic use thereof
IL215609A0 (en) Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof
IL220448A (en) Pyridine [3,2 - d] Pyrimidine - 7 (8h) - Their medical uses and uses
IL219116A (en) 5h– oxo- (Theo / oxa) Zulu [a – 2,3] ortho-compressed pyrimidine with other rings and their use for treating anemia and tissue damage caused by ischemic diseases
IL197500A0 (en) Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof
IL206669A0 (en) 6-HETEROCYCLIC IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
IL215733A0 (en) 1-pyrazolo[4,3-c]isoquinoline derivatives, preparation thereof and therapeutic use thereof
ZA201100251B (en) Substituted 1-benzyl-cinnolin-4(1h)-one derivatives,preparation thereof,and therapeutic use thereof
PL2477990T3 (pl) Pochodne 5-fenylopirazolopirydyny, ich wytwarzanie oraz ich zastosowanie terapeutyczne
IL206672A0 (en) N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
DK2310395T3 (da) 9-Substituerede 5-carboxyoxadiazinoquinolonderivater, deres fremstilling samt deres anvendelse som antibakterielle midler